NorthView Acquisition Corporation
NVAC
Other OTC2.50
USD
-9.61
- -
CIK
0001859807
ISIN
US66718N1037
CUSIP
66718N103
Return %
Stock
S&P500
1Y
-78.81
26.84
3Y
-74.75
77.03
5Y
-74.25
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jack E. Stover CPA
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 207 West 25th Street New York City NY United States of America 10001
- IPO Date
- Jan 24, 2022
- CIK
- 0001859807
- Website
- northviewac.com
- Similar Companies
- Business
- NorthView Acquisition Corporation (NVAC), a blank-check company formed in 2021 and headquartered at 207 West 25th Street, New York, New York, focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with a particular emphasis on healthcare innovation targets. As a subsidiary of NorthView Sponsor I, LLC, the company operates without significant ongoing operations prior to completing an initial business combination; it leverages investor capital raised through its initial public offering to pursue strategic opportunities across various industries, including digital health and personalized medicine. Geographically, NorthView Acquisition Corporation conducts its activities primarily from the United States, targeting domestic and potentially international merger candidates that align with its management's expertise in capital markets and sector-specific value creation. The company's core activities center on identifying, evaluating, negotiating, and executing business combinations that meet predefined financial and strategic criteria; it generates revenue primarily through transaction-related fees, sponsor incentives, and post-merger equity upon successful de-SPAC integration. NorthView Acquisition Corporation employs a disciplined due diligence process, supported by its management team led by Co-Founder and CEO Jack E. Stover and Co-Founder, Executive Vice President, and CFO Fred S. Knechtel, to screen potential targets in competitive sectors like healthcare where market inefficiencies or emerging trends offer growth potential. Its structure as a special purpose acquisition company provides public market access to high-potential private businesses while maintaining flexibility in deal execution. In recent developments, NorthView Acquisition Corporation announced a definitive business combination agreement in November 2022 with Profusa, Inc., a digital health firm developing tissue-integrated biosensors for real-time biochemical monitoring and personalized medicine, initially valued at a pro forma equity of up to $416 million. Although the merger faced delays and did not complete as initially targeted in early 2023, shareholders approved extensions in 2025, including one to June 22, 2025, and further adjournments to pursue additional time until July 2025, accompanied by sponsor contributions of $30,000 to the trust account and amendments to its articles of incorporation and bylaws to facilitate redemptions and structural changes. The company also received a Nasdaq delisting notice for failing to complete an initial business combination within the required 36-month period, resulting in its transition to OTC trading as of mid-2025.
NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Failure to Complete Initial Business Combination
NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Quarterly Report on Form 10-Q
NorthView Acquisition Corporation Announces Exception Granted by Nasdaq to Permit to The Company to Regain Compliance with Listing Rules
NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q